BONSITY: The new name for Alvogen’s Teriparatide Injection 620 mcg/2.48 mL; same affordable alternative to FORTEO® (teriparatide injection)
Vertebrae

Efficacy and Safety

Helping patients build new bone for more than 20 years

Teriparatide—the active ingredient in BONSITY—has been a mainstay anabolic therapy for osteoporosis since 2002.1

BONSITY helps three types of patients with osteoporosis build new bone2

Studies have demonstrated the efficacy of daily teriparatide injections in postmenopausal women with osteoporosis, in men with primary or hypogonadal osteoporosis, and in men and women with glucocorticoid-induced osteoporosis.

Select an indication to see the efficacy data:

BONSITY builds new bone in postmenopausal women with osteoporosis23

A clinical study evaluated the efficacy and safety of teriparatide injection (20 mcg daily; n=541) compared with placebo (n=544) in postmenopausal women. Patients were studied for a median of 19 months and a maximum of 24 months. In addition to study drug or placebo, patients took daily calcium and vitamin D supplements.

Middle-aged woman with red glasses and short dark hair and a red shirt
Actor portrayal.
Teriparatide reduces fracture risk in postmenopausal women
9.3%
Absolute risk reduction in new vertebral fractures
9.3% ARR (95% CI: 5.5-13.1) and 65% RRR (95% CI: 45-78) of 1 or more new vertebral fractures (fracture incidence: 5.0% teriparatidea vs 14.3% placebo).
Teriparatide (n=444) vs placebo (n=448).
2.9%
Absolute risk reduction in nonvertebral fractures
2.9% ARR and 53% RRR of any nonvertebral fracture (fracture incidenceb: 2.6% teriparatide vs 5.5% placebo).
Teriparatide (n=541) vs placebo (n=544).
ARR=absolute risk reduction; RRR=relative risk reduction.
ap≤0.001 compared with placebo.
bp<0.05.
Teriparatide improves bone mineral density (BMD) in postmenopausal women
Lumbar spine
9.7%
Teriparatide
(n=541)
(p<0.001)
vs
1.1%
Placebo
(n=544)
Femoral neck
2.8%
Teriparatide
(n=541)
(p<0.05)
vs
-0.7%
Placebo
(n=544)
Total hip
2.6%
Teriparatide
(n=541)
(p<0.05)
vs
-1.0%
Placebo
(n=544)
Data represent mean percent change in BMD from baseline to endpoint (median duration of treatment: 19 months).

BONSITY increases bone mass in men with primary or hypogonadal osteoporosis23

A randomized study compared BMD changes in men treated with 20 mcg teriparatide daily via subcutaneous injection (n=151) compared with placebo (n=147) for a median of 10 months. Study participants also received daily vitamin D and calcium supplements.

Middle-aged man with a mustache wearing a blue plaid shirt
Actor portrayal.
Mean percent change in BMD in men
Lumbar spine
5.9%
Teriparatide
(n=151)
(p<0.001)
vs
0.5%
Placebo
(n=147)
Femoral neck
1.5%
Teriparatide
(n=151)
(p<0.05)
vs
0.3%
Placebo
(n=147)
Total hip
1.2%
Teriparatide
(n=151)
vs
0.5%
Placebo
(n=147)
Data represent mean percent change in BMD from baseline to endpoint (median duration of treatment: 10 months).

BONSITY builds bone mass in men and women with corticosteroid-induced osteoporosis23

In an 18-month trial, men and women receiving sustained glucocorticoid therapy for chronic rheumatologic, respiratory, or other conditions were treated with 20 mcg teriparatide daily via subcutaneous injection (n=214). Patients also received daily calcium and vitamin D supplements. An active comparator was also assessed, but data from that treatment are not included here.

A middle-aged woman with short gray hair in a navy blue sweater wrapping her arms around a middle-aged man in a light blue sweater with a white beard and glasses
Actor portrayals.
Mean percent change in BMD in men and women on sustained glucocorticoid therapy
Lumbar spine
7.2%
Teriparatide
(n=214)
(p<0.001)
Femoral neck
3.7%
Teriparatide
(n=214)
(p<0.001)
Total hip
3.6%
Teriparatide
(n=214)
(p<0.001)
Data represent mean percent change in BMD from baseline to endpoint (18 months).

Safety and tolerability of BONSITY

In clinical studies of teriparatide, the most common adverse reactions in patients taking teriparatide vs placebo include2:

Pain
21.3%
Teriparatide
(n=691)
vs
20.5%
Placebo
(n=691)
Arthralgia
10.1%
Teriparatide
(n=691)
vs
8.4%
Placebo
(n=691)
Nausea
8.5%
Teriparatide
(n=691)
vs
6.7%
Placebo
(n=691)

BONSITY is an affordable once-daily teriparatide injection

79% of Medicare Part D lives have access to BONSITY.3

Explore coverage and savings

Streamlined administration

BONSITY is designed for ease of use for both patients and caregivers.

Learn how to use

Questions about BONSITY?

Connect with a representative to help your patients build new bone with BONSITY

Request a representative
Request
a Rep

References:

  1. FORTEO® [prescribing information]. Indianapolis, IN: Eli Lilly and Company.
  2. BONSITY® [prescribing information]. Morristown, NJ: Alvogen, Inc.
  3. Data on file. Alvogen, Inc.